BriaCell: Advancing Toward Approval with Late-Stage Breast Cancer Immunotherapy [Globe and Mail, The (Toronto, Canada)]
BriaCell Therapeutics Corp. - Common Shares (BCTX)
Company Research
Source: Globe and Mail, The
BriaCell Therapeutics is in the spotlight as it advances a groundbreaking immunotherapy into Phase 3 clinical trials for metastatic breast cancer—a major step toward regulatory approval. Bria-IMT™, the company's lead candidate, is designed to work in synergy with immune checkpoint inhibitors, and has shown promising safety and efficacy in earlier studies. By tailoring treatment to patient-specific tumor markers (such as HLA matching), BriaCell is unlocking the potential of precision-guided cancer immunotherapy. Backed by strong clinical progress and a pipeline targeting other cancers, BriaCell is on the cusp of reshaping the future of advanced-stage cancer care. ? To learn more about BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) Watch their video HERE Published by BTV - The Agency Discover Investment Opportunities with BTV. Delivering engaging content to Investors for 25+ years. ? This article contains syndicated content. We have not reviewed, appr
Show less
Read more
Impact Snapshot
Event Time:
BCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCTX alerts
High impacting BriaCell Therapeutics Corp. - Common Shares news events
Weekly update
A roundup of the hottest topics
BCTX
News
- BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer ModelsGlobeNewswire
- BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR MeetingGlobeNewswire
- Briacell Therap (BCTX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BCTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" MarketBeat
- BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License [Yahoo! Finance]Yahoo! Finance
- BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License [TheStreet.com]TheStreet.com
BCTX
Sec Filings
- 3/31/26 - Form 8-K
- 3/10/26 - Form 10-Q
- 3/9/26 - Form 8-K
- BCTX's page on the SEC website